Novel targets in aggressive lymphoma

Targeting CD20 with the monoclonal antibody rituximab has improved survival in patients with aggressive B-cell lymphomas, the majority of which are cured with chemoimmunotherapy. Patients progressing through or relapsing after their treatment have a poor prognosis. Despite a number of promising nove...

Full description

Saved in:
Bibliographic Details
Published in:Hematology Am Soc Hematol Educ Program
Main Author: Maddocks, Kami
Format: Artigo
Language:Inglês
Published: American Society of Hematology 2020
Subjects:
Aggressive Lymphomas: What Novel Approaches Are Ready for Prime Time?
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7727526/
https://ncbi.nlm.nih.gov/pubmed/33275737
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/hematology.2020000093
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items